

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai HeartCare Medical Technology  
Corporation Limited**

**上海心瑋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 6609)**

**ANNOUNCEMENT PURSUANT  
TO RULES 13.51B(2) AND 13.51(2) OF THE LISTING RULES**

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51B(2) and 13.51(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to Mr. Guo Shaomu (“**Mr. Guo**”), an independent non-executive director of the Company, in relation to his capacity as an independent non-executive director of Fantasia Holdings Group Co., Limited (a company listed on the Stock Exchange, stock code: 1777) (“**Fantasia**”).

Reference is made to the regulatory announcement (the “**Regulatory Announcement**”) published by the Stock Exchange on March 6, 2025 in relation to a public censure against Fantasia, Colour Life Services Group Co., Limited (a company listed on the Stock Exchange, stock code: 1778) and certain directors or former directors of the two companies (including Mr. Guo). According to the Regulatory Announcement, the Stock Exchange found that, among others, (i) Fantasia was in breach of relevant requirements under Chapter 14 of the Listing Rules in relation to a disposal transaction and (ii) other directors and former directors of Fantasia (including Mr. Guo) breached their duties and obligations under the Listing Rules arising from the disposal transactions, additional details of which are set forth in the Regulatory Announcement. Mr. Guo has been directed to attend 15 hours of training on regulatory and legal topics including Listing Rules compliance.

For the avoidance of doubt, the Regulatory Announcement only relates to Fantasia and (other than Mr. Guo mentioned above) does not involve any director or senior management of the Company. The Regulatory Announcement has no material adverse impact on the business and/or operation of the Group.

The board of directors (other than Mr. Guo) of the Company, has reviewed the Regulatory Announcement (and the statement of disciplinary action referred therein) and taken into account the background, expertise and contributions of Mr. Guo, considers that Mr. Guo remains suitable to act as an independent non-executive director, the chairman of the remuneration committee and the member of nomination committee of the Company as (i) the findings and conclusions set out in the Regulatory Announcement do not state that Mr. Guo is unsuitable to act as a director of a company listed on the Stock Exchange; and (ii) the incidents set out in the Regulatory Announcement do not involve any act of dishonesty or fraud concerning, or cast doubt on the integrity of Mr. Guo.

Mr. Guo has confirmed to the Company that save as disclosed above, there is no other information in relation to him that shall be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, nor is there any other matter in relation thereto that shall be brought to the attention of the shareholders of the Company and the Stock Exchange.

By Order of the Board  
**Shanghai HeartCare Medical Technology Corporation Limited**  
**Wang Guohui**  
*Chairman of the Board*

Shanghai, March 6, 2025

*As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui, Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.*